Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-10-01
2010-02-02
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S424000, C546S194000, C548S542000
Reexamination Certificate
active
07655675
ABSTRACT:
Compounds of formula I:inhibit the processing of APP by gamma-secretase and hence find use in treatment of Alzheimer's disease.
REFERENCES:
patent: 6890956 (2005-05-01), Churcher et al.
patent: WO 00/50391 (2000-08-01), None
patent: WO 01/70677 (2001-09-01), None
patent: WO 02/081435 (2002-10-01), None
patent: WO 03/018543 (2003-03-01), None
patent: WO 2004/031139 (2004-04-01), None
Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 2050-2057.
Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 1992-1996.
FDA mulls drug to slow late-stage Alzheimer's [online],[retrieved on Sep. 23, 2003].Retrieved from the Internet, URL; http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/indexhtml>.
Nadin Alan John
Owens Andrew Pate
Teall Martin Richard
Anderson Rebecca L
Krovatin William
Merck Sharp & Dohme Limited
Young Shawquia
Yuro Raynard
LandOfFree
Gamma-secretase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gamma-secretase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gamma-secretase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4161130